BioNTech SE (BNTX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
114.17+2.20 (+1.96%)
At close: 4:00PM EST
113.71 -0.46 (-0.40%)
Pre-market: 6:30AM EST
| Previous close | 111.97 |
| Open | 110.51 |
| Bid | 114.18 x 900 |
| Ask | 114.25 x 800 |
| Day's range | 109.23 - 114.57 |
| 52-week range | 28.00 - 131.00 |
| Volume | 1,397,428 |
| Avg. volume | 3,345,676 |
| Market cap | 27.491B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Editor's pickYahoo Finance
Moderna expands vaccine production, sets 2022 target of 1.4B doses
Moderna announces new expansion plans, and a study for its booster shot that targets the South African variant.
- Yahoo Finance
COVID-19 vaccine manufacturing is improving, executives tell Congress
Executives from vaccine companies testified before House subcomittee on progress and hurdles in manufacturing vaccines.
- Motley Fool
2 Reasons Pfizer's COVID Vaccine Prospects Just Got Even Better
It's the exact opposite of Murphy's law (the name is "Murphy" spelled backward). Pfizer (NYSE: PFE) seems to be experiencing the effects of Yhprum's law with the COVID-19 vaccine it developed and marketed with BioNTech (NASDAQ: BNTX). Pfizer and BioNTech have delivered nothing but good news for their COVID-19 vaccine Comirnaty (BNT162b2) so far.
© 2021 Verizon Media. All rights reserved.
